OBJECTIVE: To investigate opioid use and pain scores associated with incisional injection of liposomal bupivacaine compared with bupivacaine hydrochloride after laparotomy for gynecologic malignancies.
OBJECTIVE: To investigate opioid use and pain scores associated with incisional injection of liposomal bupivacaine compared with bupivacaine hydrochloride after laparotomy for gynecologic malignancies.
METHODS:
A retrospective cohort study was conducted to compare abdominal incision infiltration with liposomal bupivacaine with bupivacaine hydrochloride after modification of a pre-existing enhanced recovery pathway. Patients undergoing staging laparotomy or complex cytoreductive surgery under the updated pathway were compared with patients treated under the original pathway (historic controls). Endpoints included cumulative opioid use (primary outcome) in oral morphine equivalents and cumulative pain score.
RESULTS:
In the complex cytoreductive cohort, median oral morphine equivalents were lower in the liposomal bupivacaine group through 24 hours (30 compared with 53.5 mg, P5.002), 48 hours (37.5 compared with 82.5 mg, P5.005), and the length of stay (62 compared with 100.5 mg, P5.006). Fewer liposomal bupivacaine patients required intravenous rescue opioids (28.9% compared with 55.6%, P,.001) or patient-controlled analgesia (4.1% compared with 33.3%, P,.001). Cumulative pain score was no different between groups through 48 hours (161 compared with 158, P5.69). Postoperative nausea and ileus were less frequent in patients receiving liposomal bupivacaine. Median hospital stay was 5 days in both groups. In the staging laparotomy cohort, cumulative opioids and cumulative pain score were no different between groups (through 48 hours: 162 compared with 161, P5.62; 38 compared with 38, P5.68, respectively). Intravenous rescue opioids (15.3% compared with 28.6%, P5.05) and patient-controlled analgesia (1.4% compared with 8.3%, P5.05) were used less frequently in the liposomal bupivacaine group. Median hospital stay was 4 days in both groups. Despite the higher cost of liposomal bupivacaine, total pharmacy costs did not differ between groups.
CONCLUSION: Abdominal incision infiltration with liposomal bupivacaine was associated with less opioid and patient-controlled analgesia use with no change in pain scores compared with bupivacaine hydrochloride after complex cytoreductive surgery for gynecologic malignancies. Improvements were also seen in patients undergoing staging laparotomy. P ain is undesirable in the postoperative period, leading to higher rates of complications, prolonged hospital stay, increased readmission rates, and higher health care costs. 1, 2 Enhanced recovery pathways include a multimodal approach to control postsurgical pain and minimize opioid requirements. In addition, infiltration of local anesthetic at the surgical site has proven efficacy. [2] [3] [4] Although effective, local anesthetics such as bupivacaine hydrochloride have a limited duration of action. Delivery systems such as elastometric pumps have been used to prolong the duration of action, but patient inconvenience, difficulty of use, intravascular catheter dislodgement, and surgical site infections have limited their use.
DepoFoam bupivacaine is an extended-release liposomal bupivacaine that was recently approved by the U.S. Food and Drug Administration for management of postoperative pain after hemorrhoidectomy and bunionectomy. 5, 6 Liposomal bupivacaine consists of microscopic multivesicles with a lipid-soluble lining and an aqueous core containing encapsulated bupivacaine, 7, 8 allowing it to be slowly released over a period of up to 72-96 hours. 9 Although this preparation is currently 37 times more expensive than bupivacaine hydrochloride, the liposomal preparation has been shown to decrease postoperative opioid requirements with some evidence for a reduction in length of stay. 5, 10, 11 To date, liposomal bupivacaine has not been tested for patients undergoing laparotomy or surgery for gynecologic cancer. The purpose of this investigation was to examine opioid use and pain scores associated with incisional injection of liposomal bupivacaine compared with bupivacaine hydrochloride within an established enhanced recovery pathway.
MATERIALS AND METHODS
A retrospective cohort study was conducted. Our existing enhanced recovery pathway was modified to replace abdominal incision infiltration with bupivacaine hydrochloride with liposomal bupivacaine. The most significant pain after laparotomy is at the abdominal incision, not the vaginal incision, and therefore we did not consider using local analgesia in the vagina. Our original enhanced recovery pathway was developed and implemented on June 20, 2011, for patients treated in the Division of Gynecologic Surgery at Mayo Clinic, Rochester, Minnesota. The detailed protocol has been reported previously. 12 As a quality improvement project, initial implementation was considered exempt from institutional review board review by the Mayo Foundation institutional review board (45 CFR 46.101, item 4). However, institutional review board approval was obtained to retrospectively collect, analyze, and publish findings. In accordance with the Minnesota Statute for Use of Medical Information in Research, only those patients who consented to the use of their medical records for research purposes were included in final analysis and publication.
Two cohorts were analyzed in this investigation: 1) staging laparotomy for gynecologic malignancies which included hysterectomy, bilateral salpingooophorectomy, lymphadenectomy, and omentectomy only; and 2) complex cytoreductive surgery, which included bowel resection, splenectomy, diaphragmatic resection, extensive peritonectomy, or all of these in addition to what was encompassed under staging laparotomy.
This retrospective cohort study was planned to include the first 200 consecutive patients treated with liposomal bupivacaine under the modified enhanced recovery pathway starting on July 29, 2013. The plan was to compare patients receiving liposomal bupivacaine with a historic referent group treated with bupivacaine hydrochloride undergoing the same types of surgery (complex cytoreductive surgery or staging laparotomy) under the original enhanced recovery pathway (June 20, 2011, to December 20, 2011), reported previously. 12 Of note, surgical techniques, surgical teams, and equipment used were not different between the two study periods. The bupivacaine hydrochloride group included 81 patients with complex cytoreductive surgery and 84 patients who underwent staging laparotomy. Assuming that two thirds of the consecutive patients treated under the modified enhanced recovery pathway with liposomal bupivacaine would have complex cytoreductive surgery (n5133) and the remaining one third staging laparotomy (n567), the study would have 80% power to detect an effect size for the difference between group means of 0.40 standard deviations among patients having complex cytoreductive surgery and 0.47 standard deviations among patients having staging laparotomy, which are consistent. The primary outcome measure, cumulative opioid use through 48 hours, had a very skewed distribution in the historical bupivacaine group and would be analyzed using a nonparametric test. However, an effect size of 0.40 would equate to nearly a moderate effect size, which is clinically meaningful.
A single 20-mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine was diluted in 160 mL of preservative-free sterile 0.9% saline for a total volume of 180 mL. A large-bore liposuction 17-gauge needle (length 7 cm; outside diameter 1.4 mm) with an atraumatic tip was used for abdominal incision infiltration with the purpose of minimizing the risk of inadvertent intravascular administration of the medication. Liposomal bupivacaine was injected separately along the fascia and beneath the skin with the needle inserted in a perpendicular orientation to the long axis of the incision and in a plane parallel to the plane of the skin. We injected half of the solution on each side of the incision using several injection sites depending on the length of the incision. Bupivacaine hydrochloride was administered following U.S. Food and Drug Administration-approved dosing guidelines (70 mL of 0.25% bupivacaine hydrochloride with epinephrine 1:200,000-175 mg bupivacaine -using a 25-gauge needle injected at the same plane as described previously).
Opioid use was the primary outcome of this study and was quantified using oral morphine equivalents. 13 Cumulative opioid use was assessed by measuring the area under the curve of oral morphine equivalents through 24 hours, 48 hours, and the remaining length of hospital stay. Pain intensity was assessed using a validated 11-point numeric rating scale from 0 (no pain) to 10 (worst possible pain). The Accordion severity grading system (contracted classification) was used to measure severity of postoperative complications; grade 3 and higher complications were considered severe. 14 A randomized, double-blind, placebo-controlled trial investigating the use of Alvimopan on gastrointestinal recovery began in January 2013 and completed accrual in July 2015 overlapping with our study (Bakkum-Gamez JN, Langstraat CL, Lemens MA, Weaver AL, McGree M, Mariani A, et al. Accelerating gastrointestinal recovery in women undergoing ovarian cancer debulking: a randomized, double-blind, placebo-controlled trial. 47th Annual Meeting of the Society of Gynecologic Oncology, San Diego, CA; 2016). 15, 16 To control for potential confounding and remove all possible biases related to the overlapping study, a sensitivity analysis was performed by comparing rates of postoperative nausea, vomiting, and ileus, hospital length of stay, and costs between patients receiving liposomal bupivacaine and bupivacaine hydrochloride controls within each cohort after excluding all participants of the Alvimopan study.
Billed services were obtained from the Mayo Clinic Rochester Cost Data Warehouse. 17, 18 This database estimates facility (hospital) costs from lineitem billed charges using department-level cost-tocharge ratios from the Medicare cost reports. To account for potential differences over time in cost-tocharge ratios and Medicare reimbursement rates, services were mapped to identical services in 2014 and assigned 2014 costs. 19 Services not mapping to identical services in 2014 were adjusted to 2014 U.S. dollars using the gross domestic product implicit price deflator. 20, 21 Costs were categorized into the Berenson-Eggers Type of Service categories. 22 Categorical variables were summarized using actual counts (%), continuous variables, using median (interquartile range), and cost data using mean (standard deviation). The Fisher exact or x 2 test was used to compare categorical variables and the Wilcoxon rank-sum test for continuous variables as appropriate. The difference in medians was estimated using the Hodges-Lehmann estimate and the 95% confidence interval (CI) for median difference was estimated using the distribution-free confidence interval by Moses. 23 The 95% CI for the difference in proportions was obtained using asymptotic methods for a CI for binomial proportions. Multivariate adjustment of costs, controlling for age, geographic region of patient's residence, marital status, insurance status, Charlson comorbidities, intraoperative blood transfusion, and estimated blood loss, was performed using generalized linear models with log link and gamma distribution. 24 The method of recycled predictions was used to generate 95% CIs for the estimated differences in mean costs. A level of P,.05 was considered statistically significant for all statistical comparisons. Statistical analyses were performed using SAS 9.4 and Stata 14.1.
RESULTS
Of 200 patients treated under the updated enhanced recovery pathway, seven were excluded from the final analyses, leaving 193 patients (patients receiving liposomal bupivacaine: 121 complex cytoreductive and 72 staging cases) for analysis (Fig. 1) . Six patients were excluded as a result of lack of research consent and one patient underwent surgery twice during the study period. Historic controls (referent group) included 81 patients who underwent complex cytoreductive surgery and 84 who underwent staging laparotomy under the original enhanced recovery pathway, which included bupivacaine hydrochloride injection. There were 34 Alvimopan study participants (17 received Alvimopan and 17 placebo) among the liposomal bupivacaine complex cytoreductive cohort and 21 (9 received Alvimopan and 12 placebo) among the liposomal bupivacaine staging laparotomy cohort. Epidural analgesia was not a required element of either enhanced recovery pathway, although two patients among the cases and two among the referent group received an epidural.
In the complex cytoreductive cohort, patient baseline, operative, and postoperative characteristics are presented in Table 1 . The liposomal bupivacaine group required less opioids to achieve comparable pain control (median through 24 hours: P5.002; through 48 hours: P5.005; through remaining hospital stay: P5.006). In fact, median cumulative opioid use in the liposomal bupivacaine cohort was almost half the use in the bupivacaine hydrochloride group at all studied time points. Furthermore, the proportion of patients who were opioid-and tramadolfree compared with opioid only or tramadol only was higher in the liposomal bupivacaine group at 24 hours (P5.01), 48 hours (P5.04), and the remaining hospital stay (P,.001) ( Table 2. ). Pain intensity, as measured by cumulative pain scores from postanesthesia care unit arrival through 24 and 48 hours postoperatively, was not different between groups despite decreased opioid requirements (Table 2) . Similarly, the percentage of patients who were "pain-free" at 24 and 48 hours was not different between groups (P5.70 and P5.13, respectively).
A smaller proportion of patients receiving liposomal bupivacaine required intravenous (IV) opioid rescue (to supplement oral opioids) for postoperative pain control compared with the bupivacaine hydrochloride group (P,.001). Of those requiring IV rescue opioids, patients who received liposomal bupivacaine were less likely to first require it in the first 24 hours postoperatively (P,.001). Finally, there was an eightfold decrease in the proportion of patients requiring patient-controlled analgesia after liposomal bupivacaine injection (P,.001).
Nausea was less frequent in patients at 24 hours (P,.001) and 48 hours (P,.001) postoperatively, but there was no difference in the frequency of emesis (Table 2) . Postoperative ileus was less common in the liposomal bupivacaine group (P5.04). After excluding patients who participated in the Alvimopan study, comparison of rates of postoperative nausea, vomiting, ileus, and hospital length of stay between groups yielded the same results ( Table 2 ).
In the staging laparotomy cohort, patient baseline, operative, and postoperative characteristics are presented in Table 1 . Although cumulative opioid use through 24 hours, 48 hours, and remaining hospital stay was not different between groups (Table 2) , more patients were opioid-and tramadol-free compared with opioid only or tramadol only among patients on postoperative day 2 (P5.006) and the remaining hospital stay (P5.005). Cumulative pain scores at 24 and 48 hours and the proportion of patients who were "pain-free" at 24 and 48 hours were not different between groups (Table 2) .
Patients receiving liposomal bupivacaine had a twofold reduction in the need for IV rescue opioids (P5.05). Among patients requiring IV rescue opioids, a lower proportion of patients who received liposomal bupivacaine required it first within the first 24 hours (P5.05) ( Table 2) . Patient-controlled analgesia use was less frequent after the introduction of liposomal bupivacaine (P5.05).
Although the frequency of nausea among the liposomal bupivacaine group was almost half the frequency of nausea observed in the bupivacaine hydrochloride group both at 24 hours (P5.002) and 48 hours (P5.001) postoperatively, the frequency of vomiting was comparable between groups (Table 2) . In contrast to the complex cytoreductive cohort, there was no difference in the proportion of patients developing postoperative ileus, and the overall rate was low (P5.34). Conclusions comparing rates of postoperative nausea, emesis, ileus, and hospital length of stay between groups did not change after excluding the Alvimopan study participants (Table 2 ).
In the complex cytoreductive cohort, neither the mean 30-day adjusted predicted costs (P5.95) nor the 30-day pharmacy costs (P5.45) differed between groups (Table 3) . However, the predicted mean procedural costs in the liposomal bupivacaine group were higher compared with the procedural costs in the Unauthorized reproduction of this article is prohibited. 
DISCUSSION
We observed that compared with bupivacaine hydrochloride, incisional injection of liposomal bupivacaine within an established enhanced recovery pathway was associated with less systemic opioid requirements, less need for IV rescue opioids, and decreased use of patient-controlled analgesia after complex cytoreductive surgery for gynecologic malignancies. In addition, more patients were opioid-and tramadol-free and pain scores did not increase. Similar but less dramatic improvements were also seen in patients undergoing staging laparotomy alone. Although there was no difference in the hospital length of stay or total hospital costs, liposomal bupivacaine was associated with less nausea and ileus. We believe these improvements were the result of the reduction in opioid requirements. Compared with before we implemented enhanced recovery in 2011, our patients' pain scores are unchanged or improved with 90% less opioid use in the first 48 hours postoperatively and a patient-controlled analgesia rate of less than 5% after a full midline laparotomy to resect advanced gynecologic malignancies. Importantly, these improvements were obtained without the higher costs and operative time associated with epidural analgesia or transversus abdominis plane blocks, which are not elements of our enhanced recovery pathway. In addition to overall patient well-being, the reduction in opioid use associated with liposomal bupivacaine as a local analgesic is particularly poignant given heightened awareness of narcotic dependence in the United States. Our findings are consistent with prior studies on liposomal bupivacaine as a single-dose surgical site injection after hemorrhoidectomy, bunionectomy, breast augmentation, inguinal hernia repair, and total knee arthroplasty. 5, 10, 11, 25, 26 Liposomal bupivacaine has been shown to be superior not only to placebo, but, more importantly, to regular bupivacaine hydrochloride. 11, 26 With regard to technique, abdominal incision infiltration with liposomal bupivacaine provided superior pain relief compared with transversus abdominis plane block after total abdominal hysterectomy. 25 In contrast to prior studies, 10 we were not able to demonstrate a reduction in hospital length of stay or cost with the use of liposomal bupivacaine. However, both hospital length of stay and hospital costs had previously been optimized through implementation of the original enhanced recovery pathway. Despite the fact that liposomal bupivacaine is 37 times more expensive than bupivacaine hydrochloride, the use of liposomal bupivacaine did not increase total pharmacy costs. This is likely to be attributed to the associated decrease in patient-controlled analgesia, total opioids, and antiemetics. However, given the higher cost of liposomal bupivacaine, it should be used judiciously, and the authors caution against its routine use for procedures such as laparoscopy, in which postoperative pain is less problematic. Economic considerations that were not specifically captured in our analyses include reductions in nursing time required to manage patient-controlled analgesia pumps and Unauthorized reproduction of this article is prohibited.
